Earlier in his career, he served as CFO at multiple publicly-traded biotech companies including Sirna Therapeutics, a genetic ...

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Greg Weaver as Chief Financial Officer ...

In terms of industry tailwinds, Trump could lessen pressure from the Federal Trade Commission on mergers and acquisitions, ...

SAN ANTONIO, November 04, 2024--bioAffinity Technologies promotes Senior VP William Bauta, Ph.D., to Chief Science Officer to ...

Affinity Technologies (BIAF) announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in ...

We think the market is overly bearish about Pfizer’s ability to right the ship, and we see shares as undervalued.

Today, the National Comprehensive Cancer Network is presenting preliminary data from a study evaluating the usability of the Health Equity Report Card (HERC) tool during the American Public Health ...

A total of 27 analyst ratings have been received for Biomarin Pharmaceutical, with the consensus rating being Outperform. The average one-year price target stands at $100.85, suggesting a potential 44 ...

Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent. Earnings per share excluding some items reached 2.86 euros (S$4.08) in the ...

Oct 10 (Reuters) - Sanofi (SASY.PA), opens new tab is closing in on a deal to sell its consumer health unit for about 15 billion euros ($16.4 billion) to U.S. private equity firm Clayton Dubilier ...